J&J/DePuy Spine debuts vertebral compression fracture treatment
This article was originally published in The Gray Sheet
Executive Summary
Worldwide launch commences May 30 at SpineWeek in Geneva of the Johnson & Johnson subsidiary's Confidence spinal cement system for treating fractures that occur when vertebrae collapse due to osteoporosis, trauma or tumors. Cleared via 510(k) in the United States and CE marked in Europe, the hydraulic-based system uses a needle to deliver a polymethylmethacrylate cement which remains highly viscous for nine minutes. J&J notes that more than half a million people get vertebral compression fractures each year in the U.S. alone, although some respond to bed rest, medication or physical therapy. J&J bought the Confidence technology from Disc-O-Tech last year (1"The Gray Sheet" Nov. 12, 2007, p. 14)
You may also be interested in...
Acquisitions In Brief
Disc-O-Tech spine asset shuffle: Johnson & Johnson subsidiary DePuy Spine on Nov. 5 announces a definitive agreement to acquire Israeli firm Disc-O-Tech Medical Technologies' Confidence system and next-generation cement delivery products in development for treatment of vertebral compression fractures. The divestiture was required by the Federal Trade Commission as part of antitrust clearance of Kyphon's December 2006 agreement to acquire Disc-O-Tech's spine technologies. Other Disc-O-Tech spine assets now belong to Medtronic, which completed its $4.2 billion acquisition of Kyphon ahead of expectations on Nov. 2 (1"The Gray Sheet" Sept. 17, 2007, In Brief). Terms of DePuy's agreement were not disclosed, but Kyphon had planned to pay $120 million for Confidence plus contingent payments (2"The Gray Sheet" Jan. 1, 2007, p. 8)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.